 TopNews Arab Emirates | FDA approves Omontys - new anemia drug for chronic kidney disease patients News-Medical.net Omontys, developed by Affymax Inc. of Palo Alto, was approved for use by adult dialysis patients with anemia caused by chronic kidney disease. There are about 400000 US kidney disease patients on dialysis. It belongs to a class of drugs called ... Nektar Reports that Partner Affymax Has Announced FDA Approval of OMONTYS ... Only Once-Monthly ESA Treatment For Dialysis Patients To Be Made Available In ... FDA Okays Affymax Anemia Drug Omontys - Update |
